Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis

Description:

This report “Antibody-Drug Conjugates 2011 – real breakthrough still to come: A Technology, Stakeholder and R&D Pipeline Analysis” published in September 2011 provides the most complete compilation of information about antibody-drug conjugate (ADC) companies, technologies and products in R&D. A comprehensive analysis of the state of the art and key trends guides the reader through this complex subject. Stakeholders in the field of antibody-drug conjugates are analysed and their contribution to the growth ADC technology and products is assessed. A critical appraisal of the clinical results of active and discontinued ADC projects and products is provided. ADC technologies and products are challenged for their commercial value and growth potential.

Scope of the report

- Drugs and Linkers Used in Antibody-Drug Conjugates
- Antibodies Used in Antibody-Drug Conjugates
- Analysis of Stakeholders in Antibody-Drug Conjugates
- Clinical Value of Antibody-Drug Conjugates
- R&D Pipeline Analysis of Antibody-Drug Conjugates
- Commercial Values of Antibody-Drug Conjugates
- Company Profiles
- Executive ADC Profiles

The recent approval of Seattle Genetics’ antibody-drug conjugate Adcetris has raised great enthusiasm among stakeholders in this field. Accelerated approval was based on stunning tumor response rates in relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma. Analysts expect strong sales of the expensive therapy. However, the FDA request post-approval studies showing that the high response rates translate into improved survival and that the clinical benefit seen in a small study population of 160 patients can be confirmed in a larger population. Although these data do not have to delivered before 2018, Genentech will be the next company after Wyeth (now Pfizer) to come up with survival data of its solid tumor ADC trastuzumab emtansine expected for 2012-2014. So far, only two controlled studies with ADC compounds have been published: one with Mylotarg failed to show a survival benefit, but t-DM1 pleased with an improved safety profile versus the combination of naked antibody with systemic chemotherapy.

Results of early stage clinical trials of a number of ADC projects promise anti-tumor activity in hematologic malignancies as well as in solid tumors, but also dose-limiting toxicities which still narrow the therapeutic window for the currently used drugs and linkers. Nevertheless, about half of the currently clinical stage ADC projects entered clinical development within the last year indicating a high interest in the industry which also is reflected by the numerous licensing deals of the technology providers with pharmaceutical and biotech companies. The attrition rate of ADC development projects so far is well within the rate in oncology, or even better. However, ADC technologies still can be improved and candidates are emerging but need more time for validation and maturation.

Features and Benefits

- Understand available drug-linker technologies
- Identify key trends of novel ADC concepts and drug-linker technologies
- Understand the complexity of the chemistry, manufacturing and control of ADC products and which approaches can taken to reduce it
- Perceive a realistic target profile of current ADC compounds and how it can be improved
- Understand which tumor antigens are targeted by ADCs and their role
- See which companies can provide solutions
- Understand the commercial value of ADC technologies and ADC products
| Table 3 Seattle Genetics ADC Technology Licensing Agreements |
| Table 4 Immunogen ADC Technology Licensing Agreement |
| Table 5 Antibody-Drug Conjugates in IND and Clinical Stages |
| Table 6 Linkers in Use for Clinical-Stage Antibody-Drug Conjugates |
| Table 7 Advantages and Disadvantages of Linkers and Cytotoxic Drugs |
| Table 8 Companies Active in R&D of New Cytotoxic Drugs for ADCs |
| Table 9 Companies Active in R&D of New Linkers for ADCs |
| Table 10 Immunogenicity of Antibody-Drug Conjugates |
| Table 11 Number of drug molecules per antibody |
| Table 12 Activities of Companies in the ADC Field |
| Table 13 Strengths & Weaknesses of Integrated ADC Technology & Product Companies |
| Table 14 Emerging ADC Technology Companies |
| Table 15 Immunoconjugate & Alternative ADC Companies |
| Table 16 Reasons for Discontinuation of Clinical Stage Antibody-Drug Conjugates |
| Table 17 Main Clinical Trials with T-DM1 in Metastatic Breast Cancer |
| Table 18 Clinical Results of phase I/II stage Antibody-Drug Conjugates |
| Table 19 Antibody-Drug Conjugates in Non-Clinical Development and Preclinical R&D |
| Table 20 Antibody-Drug Conjugates Discontinued in Clinical Stages |
| Table 21 Targets of Antibody-Drug Conjugates |
| Table 22 Immunoconjugates with Non-Antibody Targeting Moiety |

**Executive ADC Profiles**

- AEZS-108
- AGS-16M8F
- ASG-5ME
- ASG-22ME
- BAY 79-4620
- BAY 94-9343
- BIIB015
- BT-062
- CR011-vcMMAE
- CR014-vcMAE
- hRS7-SN-38
- IMGN388
- IMGN529
- IMGN853
- IMGN901
- Inotuzumab ozogamicin
- Labetuzumab-SN-38
- LIV-1 ADC
- MDX-1203
- MDX-1204
- MEDI-547
- Milatuzumab-doxorubicin
- MM-302
- PSMA-ADC
- RG7596
- SAR3419
- SAR56658
- SGN-19A
- SGN-35
- SGN-75
- Trastuzumab-DM1

**Ordering:**

Order Online - [http://www.researchandmarkets.com/reports/1925862/](http://www.researchandmarkets.com/reports/1925862/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
Web Address: http://www.researchandmarkets.com/reports/1925862/
Office Code: SCD2LPHC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 2230</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 4460</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 6691</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ___________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World